Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics | Moffitt
BeT inhibitors in ongoing early-phase clinical trials for hematologic... | Download Table
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency - ScienceDirect
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
Cancers | Free Full-Text | Role of BET Inhibitors in Triple Negative Breast Cancers | HTML
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing)
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction | Nature Communications
Bromodomain inhibitors in clinical trials | Download Table
Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects
BRD4: An emerging prospective therapeutic target in glioma: Molecular Therapy - Oncolytics
Bromodomain Inhibitor Design For Epigenetic Cancer Therapies and Chemical Probes | Pomerantz Laboratory
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
